Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

471
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
471
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Prodrugs01:30

Prodrugs

2.3K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.3K
Principles of Drug Action01:24

Principles of Drug Action

5.7K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.7K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

225
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent advances in ionic liquid-based microextraction for pesticide residue analysis in food and environmental samples.

Analytical methods : advancing methods and applications·2026
Same author

Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy.

Immunotherapy·2026
Same author

Next-Generation Therapies for Genetic Diseases: The Synergy of CRISPR and Gene Therapy.

Biochemical genetics·2026
Same author

Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance.

npj antimicrobials and resistance·2025
Same author

Mapping the global landscape of molecular glues in drug discovery: a bibliometric analysis from 2010 to 2024.

Naunyn-Schmiedeberg's archives of pharmacology·2025
Same author

Advances in targeting p38 MAPK for cancer therapy: insights from molecular pharmacology and medicinal chemistry.

Molecular diversity·2025

Related Experiment Video

Updated: May 21, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

Conquering PROTAC molecular design and drugability.

Ritesh P Bhole1,2, Sonali Labhade1, Shilendra S Gurav3

  • 1Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India.

Bioanalysis
|March 21, 2025
PubMed
Summary

PROTACs (proteolysis-targeting chimeras) enable targeted protein degradation, revolutionizing drug discovery for challenging diseases. Innovations in molecular design and clinical successes show PROTACs are poised to transform precision medicine.

Keywords:
AI and machine learningE3 ligase recruitmentPrecision medicineimmunotherapyligand discoverytargeted and combination therapytargeted protein degradationtherapeutic innovation

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.3K

Related Experiment Videos

Last Updated: May 21, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.3K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Proteolysis-targeting chimeras (PROTACs) offer a novel therapeutic strategy by inducing targeted protein degradation.
  • They overcome limitations of traditional inhibitors and target previously undruggable proteins.
  • PROTACs represent a paradigm shift in drug discovery, moving beyond simple inhibition to degradation.

Purpose of the Study:

  • To explore advancements in PROTAC molecular design, including ligand discovery, E3 ligase recruitment, and ternary complex optimization.
  • To highlight emerging PROTAC technologies and their potential to enhance precision and reduce toxicity.
  • To discuss the clinical success and expanding therapeutic applications of PROTACs.

Main Methods:

  • Integration of AI-driven modeling, fragment-based drug discovery (FBDD), and structure-based drug discovery (SBDD) to accelerate PROTAC development.
  • Development of novel PROTAC modalities like PHOTACs, hypoxia-responsive systems, and antibody-PROTACs (Ab-PROTACs).
  • Analysis of clinical trial data for PROTACs in oncology and exploration of applications in other disease areas.

Main Results:

  • PROTACs demonstrate significant clinical efficacy, with examples like ARV-110 for castration-resistant prostate cancer and ARV-471 for breast cancer.
  • Emerging PROTAC technologies show promise in improving targeting specificity and minimizing off-target effects.
  • PROTACs are proving versatile, with expanding applications in neurodegenerative diseases and rare conditions.

Conclusions:

  • PROTACs are a versatile and powerful therapeutic modality with the potential to revolutionize precision medicine.
  • Continued advancements in molecular design, drugability, and addressing pharmacokinetic and safety challenges will drive their clinical impact.
  • PROTACs are expected to yield transformative therapies for a wide range of diseases.